Entering text into the input field will update the search result below

Roche's Spark Therapeutics, bluebird bio resolve suit on sickle cell disease 'Spark' campaign - Fierce Pharma

May 19, 2022 6:10 AM ETRoche Holding AG (RHHBY), RHHBFBLUEBy: Ravikash, SA News Editor

Judge gavel on law books

utah778/iStock via Getty Images

  • Switzerland's Roche (OTCQX:RHHBY) (OTCQX:RHHBF) and bluebird bio (BLUE) are resolving a trademark infringement litigation related to the Cambridge, Mass.-based gene therapy company's sickle cell disease (SCD) awareness campaign, "Be the Spark," Fierce Pharma reported.
  • Roche's gene therapy

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.